{"id":{"repo_id":"vt","oai_identifier":"oai:vtechworks.lib.vt.edu:10919/77010"},"canonical_url":"https://search.dev.ndltd.org/etd/vt/oai:vtechworks.lib.vt.edu:10919/77010","repository":{"repo_id":"vt","name":"Virginia Tech","base_url":"https://vtechworks.lib.vt.edu/oai/request"},"display":{"title":"Mild and Convenient Methods to Prepare N-Alkyl Tacrines","abstract":"Alzheimer's Disease (AD) is an irreversible, age-related neurodegenerative disorder which causes cognitive impairment and a wide variety of neuropsychiatric and behavioral disturbances. Acetylcholinesterase inhibitors (AChEI) are the mainstay for the treatment of AD. Acetylcholinesterase (AChE) catalyzes the hydrolysis of acylcholinesters with a relative specificity for acetylcholine (ACh). Observation of a deficiency of cholinergic neurotransmission in AD led to the development of AChEI as the first approved treatment for dementia symptoms. Tacrine (9-amino-1,2,3,4-tetrahydroacridine) is a reversible inhibitor of AChE. It was the first drug approved by the FDA for the treatment of cognitive symptoms of AD. Tacrine is now rarely prescribed as a drug for the treatment of AD due to its high hepatotoxicity in almost 50% of the patients. However, tacrine derivatives have considerable potential for the palliative treatment of AD. Synthesis of various bivalent tacrines led to the improvement in inhibitory potency and selectivity towards inhibition of AChE. Heptylene-linked bis-tacrine has especially shown immense promise to be an ideal AChEI. Thus dimerization of a lead compound seemed to be an ideal strategy where the compound can bind to both catalytic anionic site (CAS) and peripheral anionic site (PAS) on the AChE enzyme. However synthesis of N-alkyl derivatives of expanded tacrines like 12-chloro-2-methyl-6,7,8,9,10,11-hexahydrocycloocta[b]quinoline by the standard SNAr methods was unsuccessful and thus alternatives needed to be developed to synthesize N-alkylated and bivalent 12-chloro-2-methyl-6,7,8,9,10,11-hexahydrocycloocta[b]quinoline. Upon exploring the alternatives, N-arylation by Pd-catalysis seemed to be the most mild and convenient alternative over the standard SNAr procedures.","abstract_html":"Alzheimer's Disease (AD) is an irreversible, age-related neurodegenerative disorder which causes cognitive impairment and a wide variety of neuropsychiatric and behavioral disturbances. Acetylcholinesterase inhibitors (AChEI) are the mainstay for the treatment of AD. Acetylcholinesterase (AChE) catalyzes the hydrolysis of acylcholinesters with a relative specificity for acetylcholine (ACh). Observation of a deficiency of cholinergic neurotransmission in AD led to the development of AChEI as the first approved treatment for dementia symptoms. Tacrine (9-amino-1,2,3,4-tetrahydroacridine) is a reversible inhibitor of AChE. It was the first drug approved by the FDA for the treatment of cognitive symptoms of AD. Tacrine is now rarely prescribed as a drug for the treatment of AD due to its high hepatotoxicity in almost 50% of the patients. However, tacrine derivatives have considerable potential for the palliative treatment of AD. Synthesis of various bivalent tacrines led to the improvement in inhibitory potency and selectivity towards inhibition of AChE. Heptylene-linked bis-tacrine has especially shown immense promise to be an ideal AChEI. Thus dimerization of a lead compound seemed to be an ideal strategy where the compound can bind to both catalytic anionic site (CAS) and peripheral anionic site (PAS) on the AChE enzyme. However synthesis of N-alkyl derivatives of expanded tacrines like 12-chloro-2-methyl-6,7,8,9,10,11-hexahydrocycloocta[b]quinoline by the standard SNAr methods was unsuccessful and thus alternatives needed to be developed to synthesize N-alkylated and bivalent 12-chloro-2-methyl-6,7,8,9,10,11-hexahydrocycloocta[b]quinoline. Upon exploring the alternatives, N-arylation by Pd-catalysis seemed to be the most mild and convenient alternative over the standard SNAr procedures.","abstract_has_math":false,"creators":["Mehta, Jimit Haresh"],"institution":"Virginia Tech","degree_name":"Master of Science","degree_level":"masters","degree_discipline":"Chemistry","degree_department":"Chemistry","school":null,"contributors":[],"advisors":[],"committee_chairs":["Carlier, Paul R."],"committee_members":["Kingston, David G. I.","Dorn, Harry C."],"year":2009,"date_issued":"2009-12-18","date_published":"2009-12-18","updated_at":"2026-07-22T22:20:08Z","subjects":["N-alkyltacrines","Pd-catalysis","Tacrine","acetylcholinesterase"],"languages":["en_US"],"rights":["In Copyright"],"rights_urls":["http://rightsstatements.org/vocab/InC/1.0/"],"identifier_entries":[{"key":"dc:identifier.other","label":"Dc Identifier Other","values":["etd-05112010-032033"],"render_values":[{"text":"etd-05112010-032033","href":null,"code":true}]}]},"links":{"outbound_url":"http://hdl.handle.net/10919/77010","outbound_label":"Handle","outbound_source":"dc:identifier.uri"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor.committeechair","label":"Committee Chair","values":["Carlier, Paul R."]},{"key":"dc:contributor.committeemember","label":"Committee Member","values":["Kingston, David G. I.","Dorn, Harry C."]},{"key":"dc:contributor.department","label":"Department","values":["Chemistry"]},{"key":"dc:creator","label":"Author","values":["Mehta, Jimit Haresh"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.accessioned","label":"Dc Date Accessioned","values":["2017-04-04T19:50:56Z"]},{"key":"dc:date.available","label":"Dc Date Available","values":["2017-04-04T19:50:56Z","2016-10-07"]},{"key":"dc:date.issued","label":"Date","values":["2009-12-18"]},{"key":"dc:publisher","label":"Institution","values":["Virginia Tech"]},{"key":"dc:type","label":"Dc Type","values":["Thesis"]},{"key":"dc:type.dcmitype","label":"Dc Type Dcmitype","values":["Text"]},{"key":"thesis:degree_discipline","label":"Discipline","values":["Chemistry"]},{"key":"thesis:degree_level","label":"Degree Level","values":["masters"]},{"key":"thesis:degree_name","label":"Degree Name","values":["Master of Science"]},{"key":"thesis:institution_name","label":"Thesis Institution Name","values":["Virginia Polytechnic Institute and State University"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["N-alkyltacrines","Pd-catalysis","Tacrine","acetylcholinesterase"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language.iso","label":"Language (ISO)","values":["en_US"]},{"key":"dc:rights","label":"Dc Rights","values":["In Copyright"]},{"key":"dc:rights.uri","label":"Rights URI","values":["http://rightsstatements.org/vocab/InC/1.0/"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.other","label":"Dc Identifier Other","values":["etd-05112010-032033"]},{"key":"dc:identifier.uri","label":"Identifier URI","values":["http://hdl.handle.net/10919/77010"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["Alzheimer's Disease (AD) is an irreversible, age-related neurodegenerative disorder which causes cognitive impairment and a wide variety of neuropsychiatric and behavioral disturbances. Acetylcholinesterase inhibitors (AChEI) are the mainstay for the treatment of AD. Acetylcholinesterase (AChE) catalyzes the hydrolysis of acylcholinesters with a relative specificity for acetylcholine (ACh). Observation of a deficiency of cholinergic neurotransmission in AD led to the development of AChEI as the first approved treatment for dementia symptoms. Tacrine (9-amino-1,2,3,4-tetrahydroacridine) is a reversible inhibitor of AChE. It was the first drug approved by the FDA for the treatment of cognitive symptoms of AD. Tacrine is now rarely prescribed as a drug for the treatment of AD due to its high hepatotoxicity in almost 50% of the patients. However, tacrine derivatives have considerable potential for the palliative treatment of AD. Synthesis of various bivalent tacrines led to the improvement in inhibitory potency and selectivity towards inhibition of AChE. Heptylene-linked bis-tacrine has especially shown immense promise to be an ideal AChEI. Thus dimerization of a lead compound seemed to be an ideal strategy where the compound can bind to both catalytic anionic site (CAS) and peripheral anionic site (PAS) on the AChE enzyme. However synthesis of N-alkyl derivatives of expanded tacrines like 12-chloro-2-methyl-6,7,8,9,10,11-hexahydrocycloocta[b]quinoline by the standard SNAr methods was unsuccessful and thus alternatives needed to be developed to synthesize N-alkylated and bivalent 12-chloro-2-methyl-6,7,8,9,10,11-hexahydrocycloocta[b]quinoline. Upon exploring the alternatives, N-arylation by Pd-catalysis seemed to be the most mild and convenient alternative over the standard SNAr procedures."]},{"key":"dc:description.degree","label":"Dc Description Degree","values":["Master of Science"]},{"key":"dc:title","label":"Title","values":["Mild and Convenient Methods to Prepare N-Alkyl Tacrines"]}]}],"canonical_facts":{"dc:contributor.committeechair":["Carlier, Paul R."],"dc:contributor.committeemember":["Kingston, David G. I.","Dorn, Harry C."],"dc:contributor.department":["Chemistry"],"dc:creator":["Mehta, Jimit Haresh"],"dc:date.accessioned":["2017-04-04T19:50:56Z"],"dc:date.available":["2017-04-04T19:50:56Z","2016-10-07"],"dc:date.issued":["2009-12-18"],"dc:description.abstract":["Alzheimer's Disease (AD) is an irreversible, age-related neurodegenerative disorder which causes cognitive impairment and a wide variety of neuropsychiatric and behavioral disturbances. Acetylcholinesterase inhibitors (AChEI) are the mainstay for the treatment of AD. Acetylcholinesterase (AChE) catalyzes the hydrolysis of acylcholinesters with a relative specificity for acetylcholine (ACh). Observation of a deficiency of cholinergic neurotransmission in AD led to the development of AChEI as the first approved treatment for dementia symptoms. Tacrine (9-amino-1,2,3,4-tetrahydroacridine) is a reversible inhibitor of AChE. It was the first drug approved by the FDA for the treatment of cognitive symptoms of AD. Tacrine is now rarely prescribed as a drug for the treatment of AD due to its high hepatotoxicity in almost 50% of the patients. However, tacrine derivatives have considerable potential for the palliative treatment of AD. Synthesis of various bivalent tacrines led to the improvement in inhibitory potency and selectivity towards inhibition of AChE. Heptylene-linked bis-tacrine has especially shown immense promise to be an ideal AChEI. Thus dimerization of a lead compound seemed to be an ideal strategy where the compound can bind to both catalytic anionic site (CAS) and peripheral anionic site (PAS) on the AChE enzyme. However synthesis of N-alkyl derivatives of expanded tacrines like 12-chloro-2-methyl-6,7,8,9,10,11-hexahydrocycloocta[b]quinoline by the standard SNAr methods was unsuccessful and thus alternatives needed to be developed to synthesize N-alkylated and bivalent 12-chloro-2-methyl-6,7,8,9,10,11-hexahydrocycloocta[b]quinoline. Upon exploring the alternatives, N-arylation by Pd-catalysis seemed to be the most mild and convenient alternative over the standard SNAr procedures."],"dc:description.degree":["Master of Science"],"dc:identifier.other":["etd-05112010-032033"],"dc:identifier.uri":["http://hdl.handle.net/10919/77010"],"dc:language.iso":["en_US"],"dc:publisher":["Virginia Tech"],"dc:rights":["In Copyright"],"dc:rights.uri":["http://rightsstatements.org/vocab/InC/1.0/"],"dc:subject":["N-alkyltacrines","Pd-catalysis","Tacrine","acetylcholinesterase"],"dc:title":["Mild and Convenient Methods to Prepare N-Alkyl Tacrines"],"dc:type":["Thesis"],"dc:type.dcmitype":["Text"],"thesis:degree_discipline":["Chemistry"],"thesis:degree_level":["masters"],"thesis:degree_name":["Master of Science"],"thesis:institution_name":["Virginia Polytechnic Institute and State University"]},"updated_at":"2026-07-22T22:20:08Z"}